Auxora (zegocractin)
Acute Pancreatitis (AP) with Systemic Inflammatory Response Syndrome (SIRS)
Key Facts
About CalciMedica
CalciMedica's mission is to develop first-in-class CRAC channel inhibitors for acute inflammatory and immunologic diseases with high mortality and no approved therapies. Its primary achievement is advancing its lead candidate, Auxora (zegocractin), into Phase 2 development for acute pancreatitis and acute kidney injury, though a recent trial in AKI was discontinued. The company's strategy is to leverage its proprietary CRAC channel platform to modulate the immune response and protect against tissue cell injury, targeting critical care markets with substantial unmet need.
View full company profileAbout CalciMedica
CalciMedica's mission is to develop first-in-class CRAC channel inhibitors for acute inflammatory and immunologic diseases with high mortality and no approved therapies. Its primary achievement is advancing its lead candidate, Auxora (zegocractin), into Phase 2 development for acute pancreatitis and acute kidney injury, though a recent trial in AKI was discontinued. The company's strategy is to leverage its proprietary CRAC channel platform to modulate the immune response and protect against tissue cell injury, targeting critical care markets with substantial unmet need.
View full company profile